Clyde Wright
Concepts (354)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 21 | 2024 | 383 | 7.430 |
Why?
| | Acetaminophen | 15 | 2025 | 268 | 7.160 |
Why?
| | NF-kappa B | 23 | 2024 | 691 | 7.140 |
Why?
| | Respiratory Distress Syndrome, Newborn | 12 | 2023 | 106 | 6.920 |
Why?
| | Endotoxemia | 10 | 2024 | 86 | 6.210 |
Why?
| | Pulmonary Surfactants | 10 | 2023 | 106 | 5.660 |
Why?
| | I-kappa B Proteins | 13 | 2022 | 81 | 4.650 |
Why?
| | Liver | 16 | 2024 | 1943 | 4.190 |
Why?
| | Continuous Positive Airway Pressure | 12 | 2022 | 83 | 3.720 |
Why?
| | Ductus Arteriosus, Patent | 8 | 2024 | 52 | 3.700 |
Why?
| | Lung Injury | 7 | 2022 | 219 | 3.130 |
Why?
| | Lung | 20 | 2025 | 4060 | 2.930 |
Why?
| | Immunity, Innate | 10 | 2024 | 828 | 2.770 |
Why?
| | Infant, Premature, Diseases | 5 | 2021 | 101 | 2.740 |
Why?
| | Infant, Newborn | 46 | 2024 | 6079 | 2.680 |
Why?
| | Noninvasive Ventilation | 5 | 2022 | 51 | 2.550 |
Why?
| | Infant, Premature | 15 | 2024 | 574 | 2.480 |
Why?
| | Signal Transduction | 19 | 2025 | 5079 | 2.250 |
Why?
| | Hyperoxia | 7 | 2017 | 90 | 1.920 |
Why?
| | Transcription Factor RelA | 4 | 2024 | 87 | 1.840 |
Why?
| | Animals, Newborn | 13 | 2024 | 844 | 1.800 |
Why?
| | Surface-Active Agents | 8 | 2023 | 91 | 1.730 |
Why?
| | Infant, Extremely Premature | 8 | 2024 | 66 | 1.720 |
Why?
| | Mice, Inbred ICR | 12 | 2021 | 119 | 1.710 |
Why?
| | Ibuprofen | 5 | 2024 | 84 | 1.490 |
Why?
| | Lipopolysaccharides | 9 | 2024 | 886 | 1.440 |
Why?
| | Biological Products | 3 | 2021 | 216 | 1.420 |
Why?
| | Toll-Like Receptor 4 | 3 | 2023 | 273 | 1.390 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2022 | 137 | 1.380 |
Why?
| | Oxygen | 6 | 2022 | 931 | 1.370 |
Why?
| | Macrophages | 7 | 2020 | 1547 | 1.260 |
Why?
| | Apoptosis | 6 | 2024 | 2553 | 1.260 |
Why?
| | Neonatology | 2 | 2021 | 29 | 1.200 |
Why?
| | Airway Extubation | 2 | 2020 | 57 | 1.150 |
Why?
| | NF-kappa B p50 Subunit | 4 | 2023 | 26 | 1.140 |
Why?
| | Mice | 29 | 2025 | 17787 | 1.130 |
Why?
| | Evidence-Based Medicine | 4 | 2021 | 740 | 1.130 |
Why?
| | Animals | 39 | 2025 | 36940 | 1.090 |
Why?
| | Inflammation | 4 | 2024 | 2837 | 1.080 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2024 | 1242 | 1.050 |
Why?
| | Infant, Newborn, Diseases | 2 | 2019 | 113 | 0.990 |
Why?
| | Cytochrome P-450 CYP2E1 | 5 | 2025 | 31 | 0.970 |
Why?
| | Pregnancy | 14 | 2024 | 6763 | 0.890 |
Why?
| | Humans | 70 | 2024 | 137585 | 0.890 |
Why?
| | Mice, Inbred C57BL | 12 | 2025 | 5757 | 0.850 |
Why?
| | Transcription Factor AP-1 | 1 | 2024 | 92 | 0.840 |
Why?
| | Fetal Growth Retardation | 4 | 2024 | 565 | 0.810 |
Why?
| | Physician's Role | 2 | 2021 | 211 | 0.810 |
Why?
| | Disease Models, Animal | 12 | 2024 | 4295 | 0.800 |
Why?
| | Gene Expression Regulation | 8 | 2021 | 2607 | 0.790 |
Why?
| | Interleukin-1alpha | 2 | 2020 | 58 | 0.770 |
Why?
| | Premature Birth | 3 | 2022 | 333 | 0.740 |
Why?
| | Interleukin-1beta | 3 | 2020 | 372 | 0.730 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2021 | 283 | 0.720 |
Why?
| | Streptozocin | 1 | 2021 | 21 | 0.720 |
Why?
| | Selenoproteins | 1 | 2020 | 7 | 0.700 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2024 | 79 | 0.660 |
Why?
| | Toll-Like Receptor 9 | 1 | 2020 | 32 | 0.650 |
Why?
| | Monocytes | 1 | 2023 | 563 | 0.650 |
Why?
| | Chorioamnionitis | 1 | 2020 | 42 | 0.650 |
Why?
| | Ovarian Follicle | 1 | 2020 | 72 | 0.640 |
Why?
| | Oxidative Stress | 3 | 2017 | 1317 | 0.640 |
Why?
| | Acidosis | 1 | 2020 | 101 | 0.610 |
Why?
| | Uterus | 1 | 2020 | 215 | 0.600 |
Why?
| | Oximetry | 2 | 2017 | 96 | 0.600 |
Why?
| | Emphysema | 1 | 2019 | 106 | 0.600 |
Why?
| | Inflammation Mediators | 3 | 2019 | 513 | 0.580 |
Why?
| | I-kappa B Kinase | 2 | 2021 | 55 | 0.570 |
Why?
| | Interferon-beta | 1 | 2018 | 92 | 0.570 |
Why?
| | Gestational Age | 4 | 2024 | 910 | 0.570 |
Why?
| | Calcium Signaling | 1 | 2020 | 249 | 0.560 |
Why?
| | Treatment Failure | 2 | 2019 | 356 | 0.560 |
Why?
| | Fetus | 4 | 2020 | 806 | 0.560 |
Why?
| | Respiration, Artificial | 5 | 2022 | 645 | 0.550 |
Why?
| | Sugars | 1 | 2018 | 41 | 0.550 |
Why?
| | Beverages | 1 | 2018 | 69 | 0.550 |
Why?
| | Mediastinal Emphysema | 1 | 2017 | 7 | 0.540 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 250 | 0.540 |
Why?
| | Respiration | 2 | 2018 | 199 | 0.530 |
Why?
| | Gene Expression | 3 | 2024 | 1502 | 0.520 |
Why?
| | Peer Review, Research | 1 | 2017 | 43 | 0.520 |
Why?
| | Standard of Care | 1 | 2017 | 72 | 0.520 |
Why?
| | Infant, Small for Gestational Age | 1 | 2017 | 92 | 0.510 |
Why?
| | Insulin-Secreting Cells | 1 | 2021 | 377 | 0.510 |
Why?
| | Respiratory System | 1 | 2017 | 157 | 0.500 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 243 | 0.500 |
Why?
| | Immune Tolerance | 1 | 2018 | 363 | 0.500 |
Why?
| | Asphyxia Neonatorum | 1 | 2016 | 17 | 0.490 |
Why?
| | Male | 26 | 2024 | 67762 | 0.490 |
Why?
| | Intensive Care Units, Neonatal | 4 | 2022 | 257 | 0.480 |
Why?
| | Cyclooxygenase 2 | 1 | 2016 | 178 | 0.470 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 306 | 0.470 |
Why?
| | Mice, Knockout | 4 | 2025 | 3015 | 0.470 |
Why?
| | Milk, Human | 1 | 2017 | 158 | 0.470 |
Why?
| | Hypothermia, Induced | 1 | 2016 | 80 | 0.450 |
Why?
| | Child Advocacy | 2 | 2005 | 32 | 0.450 |
Why?
| | Nitric Oxide | 3 | 2019 | 915 | 0.450 |
Why?
| | Fetal Diseases | 1 | 2016 | 173 | 0.440 |
Why?
| | NF-KappaB Inhibitor alpha | 4 | 2020 | 54 | 0.430 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 617 | 0.430 |
Why?
| | Intestinal Atresia | 1 | 2014 | 15 | 0.430 |
Why?
| | Infant | 10 | 2024 | 9465 | 0.430 |
Why?
| | Sex Characteristics | 1 | 2019 | 762 | 0.430 |
Why?
| | Endothelin-1 | 1 | 2015 | 182 | 0.430 |
Why?
| | Calcium | 1 | 2020 | 1199 | 0.420 |
Why?
| | Interleukin-6 | 3 | 2025 | 778 | 0.420 |
Why?
| | Resuscitation | 1 | 2016 | 251 | 0.410 |
Why?
| | Ethics Committees, Research | 1 | 2013 | 42 | 0.410 |
Why?
| | Visual Perception | 1 | 2015 | 160 | 0.400 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2013 | 68 | 0.400 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 192 | 0.400 |
Why?
| | Caloric Restriction | 2 | 2024 | 124 | 0.400 |
Why?
| | Intestine, Small | 1 | 2014 | 156 | 0.390 |
Why?
| | Fibroblasts | 3 | 2015 | 996 | 0.390 |
Why?
| | Hepatocytes | 3 | 2024 | 220 | 0.390 |
Why?
| | Pediatrics | 3 | 2005 | 1101 | 0.380 |
Why?
| | Catheterization, Peripheral | 1 | 2013 | 109 | 0.380 |
Why?
| | Abnormalities, Multiple | 1 | 2014 | 189 | 0.380 |
Why?
| | Female | 25 | 2024 | 73304 | 0.370 |
Why?
| | Phospholipids | 1 | 2013 | 223 | 0.370 |
Why?
| | Respiration Disorders | 1 | 2012 | 77 | 0.370 |
Why?
| | Urinary Bladder | 1 | 2014 | 183 | 0.360 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2018 | 1477 | 0.360 |
Why?
| | Fetal Blood | 2 | 2024 | 327 | 0.360 |
Why?
| | Colon | 1 | 2014 | 282 | 0.360 |
Why?
| | Clinical Competence | 1 | 2019 | 1118 | 0.350 |
Why?
| | Biomarkers | 3 | 2024 | 4149 | 0.350 |
Why?
| | Neuropsychological Tests | 1 | 2015 | 1023 | 0.330 |
Why?
| | Microcirculation | 1 | 2010 | 149 | 0.330 |
Why?
| | Patient Safety | 1 | 2013 | 314 | 0.320 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2021 | 173 | 0.320 |
Why?
| | Glycolysis | 2 | 2021 | 321 | 0.310 |
Why?
| | RAW 264.7 Cells | 2 | 2020 | 50 | 0.310 |
Why?
| | Cells, Cultured | 5 | 2019 | 4193 | 0.310 |
Why?
| | Analgesics, Non-Narcotic | 3 | 2024 | 125 | 0.300 |
Why?
| | Cell Line | 4 | 2017 | 2847 | 0.300 |
Why?
| | Body Mass Index | 1 | 2017 | 2389 | 0.300 |
Why?
| | Indomethacin | 3 | 2024 | 81 | 0.290 |
Why?
| | Curriculum | 2 | 2005 | 992 | 0.290 |
Why?
| | Hydrocortisone | 2 | 2020 | 322 | 0.280 |
Why?
| | MicroRNAs | 2 | 2024 | 692 | 0.280 |
Why?
| | Cognition | 1 | 2015 | 1153 | 0.260 |
Why?
| | Cytokines | 3 | 2023 | 2085 | 0.260 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 927 | 0.250 |
Why?
| | Gene Silencing | 2 | 2021 | 195 | 0.250 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2020 | 139 | 0.250 |
Why?
| | Biological Evolution | 1 | 2009 | 474 | 0.230 |
Why?
| | Endothelial Cells | 1 | 2010 | 785 | 0.230 |
Why?
| | History, 20th Century | 2 | 2017 | 325 | 0.230 |
Why?
| | Cell Survival | 3 | 2021 | 1120 | 0.230 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2020 | 860 | 0.230 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2025 | 93 | 0.230 |
Why?
| | Internship and Residency | 2 | 2005 | 1147 | 0.220 |
Why?
| | Patient Advocacy | 1 | 2005 | 76 | 0.220 |
Why?
| | Cell Nucleus | 2 | 2019 | 620 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2024 | 55 | 0.210 |
Why?
| | RNA, Messenger | 4 | 2024 | 2833 | 0.210 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2024 | 72 | 0.210 |
Why?
| | STAT3 Transcription Factor | 1 | 2025 | 206 | 0.210 |
Why?
| | Toll-Like Receptor 1 | 1 | 2023 | 12 | 0.200 |
Why?
| | Zymosan | 1 | 2023 | 65 | 0.200 |
Why?
| | Intensive Care, Neonatal | 1 | 2023 | 40 | 0.200 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2023 | 85 | 0.190 |
Why?
| | Infant, Low Birth Weight | 1 | 2023 | 141 | 0.190 |
Why?
| | Toll-Like Receptors | 1 | 2023 | 185 | 0.190 |
Why?
| | Ligation | 1 | 2022 | 92 | 0.190 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2024 | 201 | 0.190 |
Why?
| | Age Factors | 2 | 2020 | 3295 | 0.190 |
Why?
| | Morbidity | 2 | 2021 | 324 | 0.180 |
Why?
| | Hepatic Veins | 1 | 2021 | 33 | 0.180 |
Why?
| | Dilatation | 1 | 2022 | 67 | 0.180 |
Why?
| | Dyspnea | 1 | 2023 | 254 | 0.180 |
Why?
| | Insulinoma | 1 | 2021 | 26 | 0.180 |
Why?
| | Feces | 1 | 2024 | 484 | 0.180 |
Why?
| | Chemokine CXCL10 | 1 | 2021 | 39 | 0.180 |
Why?
| | Transcription Factors | 1 | 2009 | 1719 | 0.170 |
Why?
| | Vascular Malformations | 1 | 2021 | 52 | 0.170 |
Why?
| | Glutathione Peroxidase | 1 | 2020 | 43 | 0.170 |
Why?
| | TNF Receptor-Associated Factor 1 | 1 | 2020 | 8 | 0.170 |
Why?
| | Chemokine CCL3 | 1 | 2020 | 16 | 0.170 |
Why?
| | C-Reactive Protein | 1 | 2023 | 410 | 0.170 |
Why?
| | Selenium | 1 | 2020 | 43 | 0.170 |
Why?
| | Ventilator Weaning | 1 | 2020 | 36 | 0.170 |
Why?
| | Portal Vein | 1 | 2021 | 120 | 0.170 |
Why?
| | Oxidative Phosphorylation | 1 | 2021 | 193 | 0.160 |
Why?
| | Homeostasis | 1 | 2024 | 621 | 0.160 |
Why?
| | Calcineurin Inhibitors | 1 | 2020 | 72 | 0.160 |
Why?
| | Intermittent Positive-Pressure Ventilation | 1 | 2019 | 11 | 0.160 |
Why?
| | Chelating Agents | 1 | 2020 | 75 | 0.160 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2020 | 143 | 0.160 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2021 | 195 | 0.160 |
Why?
| | Norepinephrine | 1 | 2020 | 204 | 0.160 |
Why?
| | Primary Cell Culture | 1 | 2020 | 171 | 0.160 |
Why?
| | Proteolysis | 1 | 2020 | 177 | 0.150 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2019 | 110 | 0.150 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 350 | 0.150 |
Why?
| | Chemokine CXCL1 | 1 | 2019 | 76 | 0.150 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2018 | 16 | 0.150 |
Why?
| | Mitochondria | 1 | 2025 | 948 | 0.150 |
Why?
| | Cytosol | 1 | 2019 | 226 | 0.150 |
Why?
| | Spleen | 1 | 2020 | 514 | 0.150 |
Why?
| | Morphogenesis | 1 | 2019 | 166 | 0.150 |
Why?
| | STAT1 Transcription Factor | 1 | 2018 | 72 | 0.150 |
Why?
| | Weight Gain | 2 | 2023 | 519 | 0.150 |
Why?
| | Delivery Rooms | 1 | 2018 | 7 | 0.140 |
Why?
| | Receptors, CCR2 | 1 | 2018 | 40 | 0.140 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2018 | 20 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 605 | 0.140 |
Why?
| | Rotation | 1 | 2018 | 117 | 0.140 |
Why?
| | Consensus | 1 | 2021 | 683 | 0.140 |
Why?
| | Protective Agents | 1 | 2018 | 41 | 0.140 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 79 | 0.140 |
Why?
| | Sheep | 1 | 2020 | 856 | 0.140 |
Why?
| | Overnutrition | 1 | 2017 | 30 | 0.140 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2018 | 145 | 0.130 |
Why?
| | Hypertension, Pulmonary | 2 | 2019 | 1910 | 0.130 |
Why?
| | Pennsylvania | 1 | 2017 | 116 | 0.130 |
Why?
| | Ductus Arteriosus | 1 | 2017 | 73 | 0.130 |
Why?
| | Parturition | 1 | 2017 | 71 | 0.130 |
Why?
| | Conservative Treatment | 1 | 2017 | 33 | 0.130 |
Why?
| | Positive-Pressure Respiration | 1 | 2017 | 80 | 0.130 |
Why?
| | Calibration | 1 | 2017 | 146 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 697 | 0.130 |
Why?
| | Protective Factors | 1 | 2016 | 93 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2018 | 347 | 0.130 |
Why?
| | Primary Prevention | 1 | 2018 | 196 | 0.130 |
Why?
| | History, 21st Century | 1 | 2017 | 213 | 0.120 |
Why?
| | Health Status Disparities | 1 | 2019 | 289 | 0.120 |
Why?
| | Time-to-Treatment | 1 | 2018 | 205 | 0.120 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 622 | 0.120 |
Why?
| | Vascular Remodeling | 1 | 2018 | 193 | 0.120 |
Why?
| | Up-Regulation | 1 | 2019 | 843 | 0.120 |
Why?
| | Precision Medicine | 1 | 2019 | 429 | 0.120 |
Why?
| | Macaca mulatta | 1 | 2016 | 166 | 0.120 |
Why?
| | Cholestasis | 1 | 2018 | 235 | 0.120 |
Why?
| | Cell Proliferation | 3 | 2011 | 2475 | 0.110 |
Why?
| | Administration, Oral | 1 | 2017 | 816 | 0.110 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.110 |
Why?
| | Periodicals as Topic | 1 | 2017 | 211 | 0.110 |
Why?
| | Prune Belly Syndrome | 1 | 2014 | 8 | 0.110 |
Why?
| | Body Composition | 1 | 2018 | 684 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 86 | 0.110 |
Why?
| | Adult | 5 | 2024 | 37929 | 0.100 |
Why?
| | Interleukins | 1 | 2015 | 250 | 0.100 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 3412 | 0.100 |
Why?
| | Syndrome | 1 | 2014 | 358 | 0.100 |
Why?
| | Breast Feeding | 1 | 2017 | 440 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1587 | 0.100 |
Why?
| | Pilot Projects | 1 | 2018 | 1710 | 0.100 |
Why?
| | Kidney | 1 | 2020 | 1468 | 0.100 |
Why?
| | Child | 4 | 2018 | 21935 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 971 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2031 | 0.100 |
Why?
| | Brain Injuries | 1 | 2017 | 494 | 0.100 |
Why?
| | Hydrogen Peroxide | 1 | 2014 | 328 | 0.100 |
Why?
| | Rats | 2 | 2013 | 5647 | 0.090 |
Why?
| | Culture Media, Serum-Free | 1 | 2012 | 48 | 0.090 |
Why?
| | Gene Knock-In Techniques | 1 | 2012 | 56 | 0.090 |
Why?
| | Risk Assessment | 2 | 2019 | 3457 | 0.090 |
Why?
| | Retinopathy of Prematurity | 1 | 2013 | 142 | 0.090 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 145 | 0.090 |
Why?
| | Software | 1 | 2017 | 665 | 0.090 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2011 | 15 | 0.090 |
Why?
| | Radiography | 1 | 2014 | 822 | 0.090 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 298 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 346 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2844 | 0.080 |
Why?
| | Cohort Studies | 2 | 2019 | 5742 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2167 | 0.080 |
Why?
| | Protoporphyrins | 1 | 2009 | 16 | 0.080 |
Why?
| | Circadian Rhythm | 1 | 2014 | 468 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 246 | 0.080 |
Why?
| | Cyclin D1 | 1 | 2009 | 68 | 0.080 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 64 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1483 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2531 | 0.080 |
Why?
| | Antioxidants | 1 | 2013 | 584 | 0.080 |
Why?
| | Luciferases | 1 | 2008 | 150 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 405 | 0.070 |
Why?
| | Child, Preschool | 2 | 2018 | 11074 | 0.070 |
Why?
| | Genes, Reporter | 1 | 2008 | 269 | 0.070 |
Why?
| | Tyrosine | 1 | 2008 | 222 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 375 | 0.070 |
Why?
| | Blood Glucose | 1 | 2018 | 2186 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 307 | 0.070 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 157 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2012 | 1774 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2486 | 0.070 |
Why?
| | Aging | 1 | 2017 | 1864 | 0.070 |
Why?
| | Transfection | 1 | 2008 | 945 | 0.060 |
Why?
| | Risk Factors | 2 | 2019 | 10388 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 840 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1353 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2181 | 0.060 |
Why?
| | Wisconsin | 1 | 2005 | 101 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2011 | 1991 | 0.060 |
Why?
| | Pregnancy Trimester, Third | 1 | 2024 | 114 | 0.050 |
Why?
| | Phosphorylation | 1 | 2008 | 1759 | 0.050 |
Why?
| | Amniotic Fluid | 1 | 2024 | 96 | 0.050 |
Why?
| | Program Development | 1 | 2005 | 364 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2024 | 201 | 0.050 |
Why?
| | United States | 2 | 2013 | 14841 | 0.050 |
Why?
| | Educational Measurement | 1 | 2005 | 289 | 0.050 |
Why?
| | Diet, High-Fat | 1 | 2023 | 247 | 0.050 |
Why?
| | Child Health Services | 1 | 2004 | 184 | 0.050 |
Why?
| | DNA | 1 | 2008 | 1459 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 673 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2024 | 1066 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1783 | 0.040 |
Why?
| | Program Evaluation | 1 | 2005 | 898 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2005 | 486 | 0.040 |
Why?
| | Fetal Development | 1 | 2023 | 296 | 0.040 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2019 | 20 | 0.040 |
Why?
| | Caspases, Initiator | 1 | 2018 | 17 | 0.040 |
Why?
| | Liver X Receptors | 1 | 2018 | 31 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 1020 | 0.040 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2018 | 38 | 0.040 |
Why?
| | Ketanserin | 1 | 2018 | 12 | 0.040 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 32 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2019 | 688 | 0.040 |
Why?
| | Caspase 1 | 1 | 2018 | 144 | 0.030 |
Why?
| | Placenta | 1 | 2024 | 750 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2018 | 216 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 127 | 0.030 |
Why?
| | Caspases | 1 | 2018 | 247 | 0.030 |
Why?
| | Lipoproteins | 1 | 2018 | 168 | 0.030 |
Why?
| | Parenteral Nutrition | 1 | 2018 | 107 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3556 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 322 | 0.030 |
Why?
| | Bleomycin | 1 | 2018 | 248 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 220 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2019 | 267 | 0.030 |
Why?
| | Comet Assay | 1 | 2014 | 16 | 0.030 |
Why?
| | Prospective Studies | 1 | 2024 | 7604 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 53 | 0.020 |
Why?
| | DNA Damage | 1 | 2014 | 420 | 0.020 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 52 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 121 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1303 | 0.020 |
Why?
| | Injections | 1 | 2011 | 183 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 332 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2009 | 24 | 0.020 |
Why?
| | Early Growth Response Protein 1 | 1 | 2009 | 27 | 0.020 |
Why?
| | Hep G2 Cells | 1 | 2009 | 67 | 0.020 |
Why?
| | K562 Cells | 1 | 2009 | 89 | 0.020 |
Why?
| | Response Elements | 1 | 2009 | 91 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 176 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 810 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 301 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 767 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1272 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2024 | 15657 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2011 | 1096 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 6828 | 0.010 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|